Search Results for 'immunotherapy'
-
Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery
GEMoaB, Intellia Enter Cellular Immunotherapy Research Pact
Will combine GEMoaB's RevCAR technology platform with Intellia's genome editing technologies to discover and develop allogeneic cellular immunotherapies.Contract Pharma Staff 07.20.20
-
Bioanalytical Services | Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Coronavirus Consortium Accelerates Immunotherapy Research
To leverage Carterra’s LSA platform to screen hundreds of antibodies in a few days as CoVIC seeks to find therapeutic candidates for COVID-19 in just weeks03.31.20
-
Breaking News
Shimadzu, Providence Partner to Advance Immunotherapy Research
Developing technologies to identify cancer antigens.Shimadzu 01.14.20
-
Breaking News | Collaborations & Alliances | Drug Development
Genentech Selects Affimed Target in Immunotherapy Alliance
Genentech is responsible for clinical development and commercialization worldwide11.08.19
-
Breaking News | Drug Development | Drug Discovery | Industry News
Celgene, Dragonfly Expand Immunotherapy Alliance
Celgene has the option to license exclusive rights to products using Dragonfly's TriNKET platform for four new targets11.14.18
-
Biologics, Proteins, Vaccines
Will Immunotherapy Knock Out Cancer?
Innovative immunotherapy companies discuss with WuXi AppTec what’s next for this rapidly developing field ahead of BIO 2017.Online Exclusives06.14.17
-
Collaborations & Alliances | Drug Development
Amgen, Immatics in Next-gen Immunotherapy Alliance
Aims to develop next-gen T-cell engaging bispecific immunotherapies targeting multiple cancers01.09.17
-
Clinical Trials | Drug Development
Rethinking Immunotherapy Clinical Endpoints in Oncology Studies
Chris Smyth and Joy Yucaitis of Novella Clinical evaluate criteria, regulations, and limitationsChris Smyth, Ph.D. and Joy Yucaitis, Novella Clinical 10.28.16
-
Clinical Trials | Drug Development
Mastering Immunotherapy Clinical Trials: Dosing and Response
Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trialsOnline Exclusives Kristin Brooks, Contract Pharma 08.01.16
-
Clinical Trials | Drug Development
Mastering Immunotherapy Clinical Trials: Protocol Design
Andrew Zupnick of Novella Clinical discusses thorny questions about protocol design for immunotherapy clinical trialsOnline Exclusives Kristin Brooks, Contract Pharma 07.25.16
